• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical implications of EGFR-associated MAPK/ERK pathway in multiple primary lung cancer.

作者信息

Liang Naixin, Bing Zhongxing, Wang Yadong, Liu Xinyu, Guo Chao, Cao Lei, Xu Yuan, Song Yang, Gao Chao, Tian Zhenhuan, Wu Pancheng, Xue Jianchao, Li Bowen, Jia Ziqi, Yang Xiaoying, Wu Yijun, Yu Ruoying, Liu Rui, Chen Xiaoxi, Ou Qiuxiang, Bao Hua, Wu Xue, Cao Zhili, Li Ji, Li Shanqing

机构信息

Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.

Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.

出版信息

Clin Transl Med. 2022 May;12(5):e847. doi: 10.1002/ctm2.847.

DOI:10.1002/ctm2.847
PMID:35538869
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9091990/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fda/9091990/6a48bd92baef/CTM2-12-e847-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fda/9091990/ad9ce23753b9/CTM2-12-e847-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fda/9091990/6a48bd92baef/CTM2-12-e847-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fda/9091990/ad9ce23753b9/CTM2-12-e847-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fda/9091990/6a48bd92baef/CTM2-12-e847-g002.jpg

相似文献

1
Clinical implications of EGFR-associated MAPK/ERK pathway in multiple primary lung cancer.表皮生长因子受体（EGFR）相关的丝裂原活化蛋白激酶/细胞外信号调节激酶（MAPK/ERK）通路在多原发性肺癌中的临床意义
Clin Transl Med. 2022 May;12(5):e847. doi: 10.1002/ctm2.847.
2
EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma.表皮生长因子受体-生长因子受体结合蛋白2蛋白共定位是一种与肺腺癌总体表皮生长因子受体表达或表皮生长因子受体突变无关的预后因素。
J Thorac Oncol. 2016 Nov;11(11):1901-1911. doi: 10.1016/j.jtho.2016.06.025. Epub 2016 Jul 20.
3
Mutational activation of the epidermal growth factor receptor down-regulates major histocompatibility complex class I expression via the extracellular signal-regulated kinase in non-small cell lung cancer.非小细胞肺癌中表皮生长因子受体的突变激活通过细胞外信号调节激酶下调主要组织相容性复合物 I 类的表达。
Cancer Sci. 2019 Jan;110(1):52-60. doi: 10.1111/cas.13860. Epub 2018 Nov 27.
4
The EGFR as a target for viral oncoproteins.表皮生长因子受体作为病毒癌蛋白的靶点。
Trends Microbiol. 1999 Nov;7(11):453-8. doi: 10.1016/s0966-842x(99)01605-4.
5
EGFR promotes the proliferation of quail follicular granulosa cells through the MAPK/extracellular signal-regulated kinase (ERK) signaling pathway.表皮生长因子受体通过丝裂原活化蛋白激酶/细胞外信号调节激酶（ERK）信号通路促进鹌鹑卵泡颗粒细胞的增殖。
Cell Cycle. 2019 Oct;18(20):2742-2756. doi: 10.1080/15384101.2019.1656952. Epub 2019 Aug 29.
6
Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer.吗啡诱导非小细胞肺癌表皮生长因子通路激活。
Anesth Analg. 2011 Dec;113(6):1353-64. doi: 10.1213/ANE.0b013e318232b35a. Epub 2011 Oct 14.
7
MAP4K4 is a novel MAPK/ERK pathway regulator required for lung adenocarcinoma maintenance.丝裂原活化蛋白激酶激酶激酶4（MAP4K4）是维持肺腺癌所必需的一种新型丝裂原活化蛋白激酶/细胞外信号调节激酶（MAPK/ERK）信号通路调节因子。
Mol Oncol. 2017 Jun;11(6):628-639. doi: 10.1002/1878-0261.12055. Epub 2017 May 2.
8
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.人类激酶组中保守的表皮生长因子受体（EGFR）E884-R958离子对的破坏会不同程度地改变信号传导和抑制剂敏感性。
Oncogene. 2009 Jan 29;28(4):518-33. doi: 10.1038/onc.2008.411. Epub 2008 Nov 17.
9
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.ERK 信号的再激活导致对 EGFR 激酶抑制剂的耐药性。
Cancer Discov. 2012 Oct;2(10):934-47. doi: 10.1158/2159-8290.CD-12-0103. Epub 2012 Sep 7.
10
Aberrant large tumor suppressor 2 (LATS2) gene expression correlates with EGFR mutation and survival in lung adenocarcinomas.异常的大肿瘤抑制因子2（LATS2）基因表达与肺腺癌中的表皮生长因子受体（EGFR）突变及生存情况相关。
Lung Cancer. 2014 Aug;85(2):282-92. doi: 10.1016/j.lungcan.2014.05.025. Epub 2014 Jun 16.

引用本文的文献

1
Germline alteration analysis reveals EPHB4R91H mutation as a key player in multiple primary lung tumors.种系改变分析显示EPHB4 R91H突变是多发性原发性肺肿瘤的关键因素。
Carcinogenesis. 2025 Jan 20;46(1). doi: 10.1093/carcin/bgae074.
2
Super multiple primary lung cancers harbor high-frequency BRAF and low-frequency EGFR mutations in the MAPK pathway.超多发原发性肺癌在丝裂原活化蛋白激酶（MAPK）通路中存在高频BRAF突变和低频表皮生长因子受体（EGFR）突变。
NPJ Precis Oncol. 2024 Oct 9;8(1):229. doi: 10.1038/s41698-024-00726-3.
3
Tumour-associated macrophages: versatile players in the tumour microenvironment.

本文引用的文献

1
Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.同步性多原发肺癌的基因组图谱及其与 TMB、PD-L1 表达和免疫细胞浸润图谱的关联。
J Immunother Cancer. 2021 Dec;9(12). doi: 10.1136/jitc-2021-003773.
2
Using DNA sequencing data to quantify T cell fraction and therapy response.利用 DNA 测序数据定量 T 细胞分数和治疗反应。
Nature. 2021 Sep;597(7877):555-560. doi: 10.1038/s41586-021-03894-5. Epub 2021 Sep 8.
3
Multiple Primary Lung Cancers: A New Challenge in the Era of Precision Medicine.
肿瘤相关巨噬细胞：肿瘤微环境中的多面手
Front Cell Dev Biol. 2023 Oct 26;11:1261749. doi: 10.3389/fcell.2023.1261749. eCollection 2023.
4
Plasma metabolomics study in screening and differential diagnosis of multiple primary lung cancer.血浆代谢组学在多原发肺癌筛查和鉴别诊断中的研究。
Int J Surg. 2023 Mar 1;109(3):297-312. doi: 10.1097/JS9.0000000000000006.
5
Multiple primary lung cancer tumors with diversified genetic mutations-complications in choosing therapeutic options.具有多种基因突变的多原发性肺癌肿瘤——治疗方案选择中的复杂性
Clin Transl Discov. 2022 Sep;2(3). doi: 10.1002/ctd2.123. Epub 2022 Aug 3.
多原发性肺癌：精准医学时代的新挑战
Cancer Manag Res. 2020 Oct 20;12:10361-10374. doi: 10.2147/CMAR.S268081. eCollection 2020.
4
Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma.肺浸润前和早期浸润性腺癌的基因组景观和免疫微环境特征。
J Thorac Oncol. 2019 Nov;14(11):1912-1923. doi: 10.1016/j.jtho.2019.07.031. Epub 2019 Aug 22.
5
Immune evasion before tumour invasion in early lung squamous carcinogenesis.肿瘤侵袭前的早期肺鳞癌免疫逃逸。
Nature. 2019 Jul;571(7766):570-575. doi: 10.1038/s41586-019-1330-0. Epub 2019 Jun 26.
6
Multiple primary lung cancer: a rising challenge.多发性原发性肺癌：一项日益严峻的挑战。
J Thorac Dis. 2019 Mar;11(Suppl 4):S523-S536. doi: 10.21037/jtd.2019.01.56.
7
Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.度伐利尤单抗作为晚期非小细胞肺癌的三线或后线治疗药物（ATLANTIC）：一项开放标签、单臂、2 期研究。
Lancet Oncol. 2018 Apr;19(4):521-536. doi: 10.1016/S1470-2045(18)30144-X. Epub 2018 Mar 12.
8
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.表皮生长因子受体（EGFR）突变和间变性淋巴瘤激酶（ALK）重排与非小细胞肺癌中PD-1通路阻断的低反应率相关：一项回顾性分析
Clin Cancer Res. 2016 Sep 15;22(18):4585-93. doi: 10.1158/1078-0432.CCR-15-3101. Epub 2016 May 25.
9
Synchronous multiple primary lung cancers with different response to gefitinib.对吉非替尼有不同反应的同步性多原发性肺癌。
Lung Cancer. 2006 Aug;53(2):245-8. doi: 10.1016/j.lungcan.2006.05.010. Epub 2006 Jun 19.